Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Novel serogroup B meningococcal vaccines are currently in late stage development and may be used in mass immunisation campaigns over the coming years. This represents an exciting development in the prevention of childhood meningitis, however monitoring the impact of these vaccines on meningococcal disease epidemiology will provide significant challenges. Although designed to prevent serogroup B meningococcal disease the vaccine antigens are not serogroup specific, creating the potential for multiple definitions of vaccine effectiveness and vaccine failure.

Original publication

DOI

10.1016/j.vaccine.2011.12.126

Type

Journal article

Journal

Vaccine

Publication Date

30/05/2012

Volume

30 Suppl 2

Pages

B67 - B72

Keywords

Humans, Meningococcal Infections, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B, Product Surveillance, Postmarketing, Sentinel Surveillance